Financial Survey: GeoVax Labs (NASDAQ:GOVX) vs. Valneva (NASDAQ:VALN)

Valneva (NASDAQ:VALN – Get Free Report) and GeoVax Labs (NASDAQ:GOVX – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Profitability

This table compares Valneva and GeoVax Labs’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Valneva -110.33% -153.20% -39.50%
GeoVax Labs N/A -1,010.68% -420.06%

Earnings & Valuation

This table compares Valneva and GeoVax Labs”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Valneva $142.94 million 3.87 -$130.33 million ($2.11) -2.75
GeoVax Labs $2.49 million 0.34 -$21.47 million ($11.34) -0.15

GeoVax Labs has lower revenue, but higher earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

11.4% of Valneva shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 14.9% of Valneva shares are owned by company insiders. Comparatively, 0.2% of GeoVax Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations for Valneva and GeoVax Labs, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Valneva 2 0 1 0 1.67
GeoVax Labs 1 1 1 0 2.00

Valneva currently has a consensus target price of $9.30, indicating a potential upside of 60.07%. GeoVax Labs has a consensus target price of $3,600.00, indicating a potential upside of 216,246.15%. Given GeoVax Labs’ stronger consensus rating and higher possible upside, analysts clearly believe GeoVax Labs is more favorable than Valneva.

Risk and Volatility

Valneva has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500. Comparatively, GeoVax Labs has a beta of 3.85, indicating that its stock price is 285% more volatile than the S&P 500.

Summary

Valneva beats GeoVax Labs on 7 of the 13 factors compared between the two stocks.

About Valneva

(Get Free Report)

Valneva is a specialty vaccine company focused on developing, manufacturing and commercializing vaccines for infectious diseases. Founded in 2013 through the combination of Vivalis and Intercell, the company is headquartered in Saint-Herblain, France, and serves markets in Europe, North America and other regions through direct operations and commercial partners. Its marketed vaccines include IXIARO, for prevention of Japanese encephalitis, and DUKORAL, an oral vaccine for cholera. Valneva also developed IXCHIQ, a vaccine to prevent disease caused by chikungunya virus, which has received regulatory authorization in the United States and Europe.

About GeoVax Labs

(Get Free Report)

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer. The company’s technology platform is based primarily on modified vaccinia Ankara (MVA) and virus-like particle (VLP) vaccine technologies, which are designed to generate broad and durable immune responses. GeoVax’s pipeline has included GEO-CM04S1, a multivalent COVID-19 vaccine candidate intended to address emerging coronavirus variants, as well as investigational vaccines for HIV, hemorrhagic fever viruses such as Ebola and Marburg, and other infectious diseases.

Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.